These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34928422)

  • 41. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
    Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
    Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents.
    Fernandez-Gutierrez B; Leon L; Madrid A; Rodriguez-Rodriguez L; Freites D; Font J; Mucientes A; Culebras E; Colome JI; Jover JA; Abasolo L
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X20962692. PubMed ID: 33613703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
    Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
    Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
    Götestam Skorpen C; Hoeltzenbein M; Tincani A; Fischer-Betz R; Elefant E; Chambers C; da Silva J; Nelson-Piercy C; Cetin I; Costedoat-Chalumeau N; Dolhain R; Förger F; Khamashta M; Ruiz-Irastorza G; Zink A; Vencovsky J; Cutolo M; Caeyers N; Zumbühl C; Østensen M
    Ann Rheum Dis; 2016 May; 75(5):795-810. PubMed ID: 26888948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
    Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
    Glück T; Müller-Ladner U
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
    [No Abstract]   [Full Text] [Related]  

  • 47. [SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments].
    Leipe J; Hoyer BF; Iking-Konert C; Schulze-Koops H; Specker C; Krüger K
    Z Rheumatol; 2020 Sep; 79(7):686-691. PubMed ID: 32845393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dosage and toxicity of antirheumatic drugs in renal insufficiency].
    Weiner SM; Bergner R
    Z Rheumatol; 2015 May; 74(4):300-9. PubMed ID: 25962451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.
    Niehues T; Horneff G; Michels H; Höck MS; Schuchmann L; ;
    Rheumatol Int; 2005 Apr; 25(3):169-78. PubMed ID: 15688190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
    Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prescribing Trends of Biologic Disease-Modifying Anti-rheumatic Drugs Using a Claims Database from 6 Million People in Japan.
    Hirata A; Ota R; Hata T; Hamada T; Nishihara M; Uchiyama K; Katsumata T
    Clin Drug Investig; 2021 Nov; 41(11):967-974. PubMed ID: 34553318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment strategies are more important than drugs in the management of rheumatoid arthritis.
    Drosos AA; Pelechas E; Voulgari PV
    Clin Rheumatol; 2020 Apr; 39(4):1363-1368. PubMed ID: 32088801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Practical problems by implementation of vaccination recommendations].
    Fendler C; Saracbasi E; Dybowski F; Heldmann F; Braun J
    Z Rheumatol; 2012 Feb; 71(2):147-50, 153-5. PubMed ID: 22370806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
    Albrecht K; Krüger K; Wollenhaupt J; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester GR; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
    Rheumatol Int; 2014 Jan; 34(1):1-9. PubMed ID: 23942828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rheumatoid arthritis: previously untreated early disease.
    Gunasekera WM; Kirwan JR
    BMJ Clin Evid; 2016 Aug; 2016():. PubMed ID: 27479367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
    Betancourt BY; Biehl A; Katz JD; Subedi A
    Rheum Dis Clin North Am; 2018 Aug; 44(3):371-391. PubMed ID: 30001781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression.
    Baker JF; George MD
    Curr Rheumatol Rep; 2019 Mar; 21(5):17. PubMed ID: 30847768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.
    Ho CTK; Mok CC; Cheung TT; Kwok KY; Yip RML;
    Clin Rheumatol; 2019 Dec; 38(12):3331-3350. PubMed ID: 31485846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.